Fig. 5: Basal caspase-2 and caspase-3 protein levels are heterogeneously expressed and do not correlate to complete remission duration in AML patients. | Cell Death Discovery

Fig. 5: Basal caspase-2 and caspase-3 protein levels are heterogeneously expressed and do not correlate to complete remission duration in AML patients.

From: Caspase-2 is a mediator of apoptotic signaling in response to gemtuzumab ozogamicin in acute myeloid leukemia

Fig. 5

Primary treatment naïve AML mononuclear cells (n = 22) were analysed for expression levels of full-length caspase-2 and full-length caspase-3 using immunoblotting. The samples illustrated in the top panel were all run on the same gel and the antibodies were run on the same membrane one at a time. Upper panel shows a immunoblot with full-length caspase-2 and full-length caspase-3 expressions in six patient samples with short (below 6 months) and long CR (above 6 months) respectively. GAPDH was used as loading control. Lower panels show the quantification of caspase-2 (left) or caspase-3 (right) expression levels in individual patients with short CR or long CR duration after normalization to GAPDH level. A two-tailed Mann- Whitney t-test was used for comparison of caspase-2 and caspase-3 expression levels in the two AML patient cohorts with p-values indicated.

Back to article page